Cargando…

Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine

Protein glycation provides a biomarker in widespread clinical use, glycated hemoglobin HbA(1c) (A1C). It is a biomarker for diagnosis of diabetes and prediabetes and of medium-term glycemic control in patients with established diabetes. A1C is an early-stage glycation adduct of hemoglobin with gluco...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabbani, Naila, Thornalley, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113047/
https://www.ncbi.nlm.nih.gov/pubmed/33707127
http://dx.doi.org/10.1016/j.redox.2021.101920
_version_ 1783690793943302144
author Rabbani, Naila
Thornalley, Paul J.
author_facet Rabbani, Naila
Thornalley, Paul J.
author_sort Rabbani, Naila
collection PubMed
description Protein glycation provides a biomarker in widespread clinical use, glycated hemoglobin HbA(1c) (A1C). It is a biomarker for diagnosis of diabetes and prediabetes and of medium-term glycemic control in patients with established diabetes. A1C is an early-stage glycation adduct of hemoglobin with glucose; a fructosamine derivative. Glucose is an amino group-directed glycating agent, modifying N-terminal and lysine sidechain amino groups. A similar fructosamine derivative of serum albumin, glycated albumin (GA), finds use as a biomarker of glycemic control, particularly where there is interference in use of A1C. Later stage adducts, advanced glycation endproducts (AGEs), are formed by the degradation of fructosamines and by the reaction of reactive dicarbonyl metabolites, such as methylglyoxal. Dicarbonyls are arginine-directed glycating agents forming mainly hydroimidazolone AGEs. Glucosepane and pentosidine, an intense fluorophore, are AGE covalent crosslinks. Cellular proteolysis of glycated proteins forms glycated amino acids, which are released into plasma and excreted in urine. Development of diagnostic algorithms by artificial intelligence machine learning is enhancing the applications of glycation biomarkers. Investigational glycation biomarkers are in development for: (i) healthy aging; (ii) risk prediction of vascular complications of diabetes; (iii) diagnosis of autism; and (iv) diagnosis and classification of early-stage arthritis. Protein glycation biomarkers are influenced by heritability, aging, decline in metabolic, vascular, renal and skeletal health, and other factors. They are applicable to populations of differing ethnicities, bridging the gap between genotype and phenotype. They are thereby likely to find continued and expanding clinical use, including in the current era of developing precision medicine, reporting on multiple pathogenic processes and supporting a precision medicine approach.
format Online
Article
Text
id pubmed-8113047
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81130472021-05-18 Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine Rabbani, Naila Thornalley, Paul J. Redox Biol Articles from the Special Issue on Oxidative stress in retina and retinal pigment epithelium in health and disease; Edited by Dr. Vera Bonilha Protein glycation provides a biomarker in widespread clinical use, glycated hemoglobin HbA(1c) (A1C). It is a biomarker for diagnosis of diabetes and prediabetes and of medium-term glycemic control in patients with established diabetes. A1C is an early-stage glycation adduct of hemoglobin with glucose; a fructosamine derivative. Glucose is an amino group-directed glycating agent, modifying N-terminal and lysine sidechain amino groups. A similar fructosamine derivative of serum albumin, glycated albumin (GA), finds use as a biomarker of glycemic control, particularly where there is interference in use of A1C. Later stage adducts, advanced glycation endproducts (AGEs), are formed by the degradation of fructosamines and by the reaction of reactive dicarbonyl metabolites, such as methylglyoxal. Dicarbonyls are arginine-directed glycating agents forming mainly hydroimidazolone AGEs. Glucosepane and pentosidine, an intense fluorophore, are AGE covalent crosslinks. Cellular proteolysis of glycated proteins forms glycated amino acids, which are released into plasma and excreted in urine. Development of diagnostic algorithms by artificial intelligence machine learning is enhancing the applications of glycation biomarkers. Investigational glycation biomarkers are in development for: (i) healthy aging; (ii) risk prediction of vascular complications of diabetes; (iii) diagnosis of autism; and (iv) diagnosis and classification of early-stage arthritis. Protein glycation biomarkers are influenced by heritability, aging, decline in metabolic, vascular, renal and skeletal health, and other factors. They are applicable to populations of differing ethnicities, bridging the gap between genotype and phenotype. They are thereby likely to find continued and expanding clinical use, including in the current era of developing precision medicine, reporting on multiple pathogenic processes and supporting a precision medicine approach. Elsevier 2021-02-26 /pmc/articles/PMC8113047/ /pubmed/33707127 http://dx.doi.org/10.1016/j.redox.2021.101920 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles from the Special Issue on Oxidative stress in retina and retinal pigment epithelium in health and disease; Edited by Dr. Vera Bonilha
Rabbani, Naila
Thornalley, Paul J.
Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine
title Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine
title_full Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine
title_fullStr Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine
title_full_unstemmed Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine
title_short Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine
title_sort protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine
topic Articles from the Special Issue on Oxidative stress in retina and retinal pigment epithelium in health and disease; Edited by Dr. Vera Bonilha
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113047/
https://www.ncbi.nlm.nih.gov/pubmed/33707127
http://dx.doi.org/10.1016/j.redox.2021.101920
work_keys_str_mv AT rabbaninaila proteinglycationbiomarkersofmetabolicdysfunctionandearlystagedeclineinhealthintheeraofprecisionmedicine
AT thornalleypaulj proteinglycationbiomarkersofmetabolicdysfunctionandearlystagedeclineinhealthintheeraofprecisionmedicine